Wenjin Xu

WenJin (Jimmy) Xu, Ph.D., is an accomplished neuroscientist with extensive experience in preclinical research and drug development. Currently serving as Associate Director and Principal Scientist at BlueRock Therapeutics since June 2021, WenJin leads the in vivo team focused on proof of concept and efficacy studies for IND-readiness and developmental drug products. Previously, WenJin held the position of Managing Scientist at PsychoGenics, overseeing preclinical therapeutic testing and coordinating multiple projects, and contributed significantly as a Scientist, studying the basal ganglia's role in Huntington's Disease. WenJin's early career included a postdoctoral research role at the Nathan Kline Institute, investigating the olfactory system's potential for early Alzheimer's detection. WenJin earned a Ph.D. in Integrative Neuroscience from Stony Brook University in 2011.